Recognizing age-related macular degeneration in primary care

  title={Recognizing age-related macular degeneration in primary care},
  author={Jill Cunningham},
  journal={Journal of the American Academy of Physician Assistants},
  • J. Cunningham
  • Published 1 March 2017
  • Medicine
  • Journal of the American Academy of Physician Assistants
ABSTRACT Age-related macular degeneration (AMD) is a disabling condition that results in central vision loss and significantly affects the quality of life for the growing population of older adults. Primary care providers play a vital role in early recognition of disease. This article reviews the risk factors, symptoms, physical examination findings, and management of AMD. Although there is no cure at this time, early referral and treatment may prevent some patients from progressing to complete… Expand
The Role of Imaging in Age-Related Macular Degeneration
The evidence suggests that oxidative stress, lipofuscin accumulation, drusen accumulation, chronic inflammation, choroidal neovascularization, and mutations of the complement contribute to the development of age-related macular degeneration. Expand
Age-related macular degeneration.
The risk factors, clinical manifestation, and current diagnostic and treatment options of age-related macular degeneration are looked at. Expand


Age‐Related Macular Degeneration: A Practical Approach to a Challenging Disease
Education regarding the clinical course of age‐related macular degeneration and accurate information with respect to the known benefits of available treatments will impart a better understanding of this disease to patients. Expand
Care of Older Adults: Role of Primary Care Physicians in the Treatment of Cataracts and Macular Degeneration
This article aims to facilitate optimal management of cataracts and age‐related macular degeneration (AMD) by providing information on indications, risk factors, referral guidelines, and treatmentsExpand
Is age‐related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment
The latest evidence to support the notion that AMD is an ocular manifestation of systemic disease processes is summarized, and the potential systemic side effects of ocular AMD therapy are discussed, of which general physicians should be aware. Expand
Complement in age-related macular degeneration: a focus on function
The evolution of the complement system is described and brought together recent research is brought together to form a picture of how changes in complement system genes and proteins affect the function ofThe complement cascade, and how this affects the development of AMD. Expand
Age related macular degeneration – challenge for future: Pathogenesis and new perspectives for the treatment
The authors present the review of the literature concerning the pathogenesis, classification, risk factors as well as perspectives for the treatment of age-related macular degeneration (AMD), and suggest that Aflibercept, or VEGF Trap-eye, may be considered an attractive alternative to other anti-VEGF agents. Expand
Nutritional supplements in age‐related macular degeneration
The present review focuses on the role of supplements in the treatment and prevention of AMD and sums up the current knowledge about the most frequently used micronutrients. Expand
Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.
Patients experiencing a longer delay between their first symptoms of CNV and their first anti-VEGF treatment have a significantly lower chance of improving vision at 6 months following anti-Vascular endothelial growth factor therapy. Expand
Age related macular degeneration
This research extends beyond current treatment options into ways of reversing retinal damage by looking at the role of light refractive error in the progression of age related macular degeneration. Expand
Stem cell based therapies for age-related macular degeneration: The promises and the challenges
Changing dead or dysfunctional RPE with healthy RPE has been shown to rescue dying photoreceptors and improve vision in animal models of retinal degeneration and possibly in AMD patients, and methods to generate stem cell-derived RPE, immune reaction against such cells, and approaches to deliver desired cells into the eye will be explored. Expand
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
When compared with control treatments, participants who received any of the three anti-VEGF agents were more likely to have gained 15 letters or more of visual acuity, lost fewer than 15 letters of visual Acuity, and had vision 20/200 or better after one year of follow up. Expand